The Oxford Academic Health Science Network’s Clinical Innovation Adoption (CIA) programme helps implement evidence-based innovation in line with NHS needs, improving patient outcomes and reducing NHS costs.
It supports changes in practice and improvement, building region-wide capability and capacity and enhancing cost-effectiveness. The programme works closely with NHS leaders in primary and secondary care, commissioners, clinical innovators, industry partners and others in line with both regional and national priorities.
Using a tried and trusted ten-step process, the programme has evaluated more than 300 innovations, taking account of potential benefits, impact on patient experience, local priorities and ease of adoption. Expert input from the team covers building the case for change, evaluation, supporting implementation and understanding and overcoming barriers to adoption.
As a result, over 30 sustainable and wide-ranging innovations have been implemented across medicines, medical devices, digital and system transformation. There are currently at least 20 active overarching projects. Focus areas include heart failure, prostate cancer, falls prevention and sleep improvement. The CIA programme is leading on five of the seven national programmes being delivered by all AHSNs – including a successful collaboration to reduce stroke risk through better identification of atrial fibrillation – as well as products added to the national Innovation and Technology Tariff, Accelerated Access Collaborative and rapid uptake products.
The CIA programme also runs a training programme for innovators – more than 150 people have benefited from this collaboration with Bucks New University and Health Education England and funding has been secured until 2021.
- Read more about Clinical Innovation Adoption and other successful Oxford AHSN programmes in ‘The first five years‘ report published in October 2018.
- Find out more in the video below or visit the Clinical Innovation Adoption website: clinicalinnovation.org.uk